Gene optimized Hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome
OwnerConnie Schmaljohninventor
Life of this patent
Estimating the term…
Loading patent…
OwnerConnie Schmaljohninventor
Estimating the term…
A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.
A method of inducing an immune response against hantavirus glycoprotein caused by HTNV virus comprising administering a vaccine for HTNV comprising:
A method of inoculating a patient for HTNV virus, comprising administering an immunogenic amount of a vaccine for HTNV comprising:
A method of inducing an immune response against hantavirus glycoprotein caused by HTNV infection in a mammal, comprising the step of administering a vaccine of SEQ ID NO:
A method of delivering a DNA vaccine against hantavirus glycoprotein;
Dependencies are inferred from the claim text.